

Date: 11/9/2021

**Subject: Update: Immunization Education Update on Pfizer-BioNTech COVID-19 Pediatric Vaccine--
ORANGE CAP**

Good Morning Immunization Partners,

CDC has shared numerous updates to clinical guidance documents regarding the use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5 through 11 years.

Morbidity and Mortality Weekly Report (MMWR)

On November 5, 2021, the recommendations for children aged 5-11 years were published in the MMWR. The report, [*The Advisory Committee on Immunization Practices' Interim Recommendations for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 years—United States, November 2021*](#), adds that the ACIP made this interim recommendation in children aged 5-11 years based on a review of the available data.

Clinical Guidance for Pfizer-BioNTech COVID-19 Vaccine for Children aged 5-11 Years

On November 3, 2021, CDC updated the [*Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States*](#). Here are some of the recent changes:

- Recommendations and clinical guidance for use of Pfizer COVID-19 Vaccine in children aged 5–11 years with updated section on [Vaccination of children and adolescents](#)
- Updated guidance on [COVID-19 vaccine dosing and schedule](#)
- Updated guidance for myocarditis and pericarditis after mRNA COVID-19 vaccination in section on [Considerations for mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna](#)
- New guidance for people who received passive antibody products in section on [COVID-19 vaccination and SARS-CoV-2 infection](#)
- Updated guidance in section on [Contraindications and precautions](#)
- Plus, more updates.

The following CDC materials are now available for your support in storage, handling, and administration of the **new pediatric Pfizer COVID-19 Vaccine for Ages 5 Through 11 Years (Orange Cap)**:

- [Standing Orders for Administering Vaccine to Persons 5 through 11 Years of Age](#)
- [Preparation and Administration Summary \(5 through 11 Years of Age\)](#)
- [Storage and Handling Summary \(5 through 11 years of age\)](#)
- [Storage and Handling labels \(5 through 11 years of age\)](#)
- [Beyond Use Date guidance and labels \(5 through 11 years of age\)](#)
- [Transporting Vaccine for Vaccination Clinics Held at Satellite, Temporary or Off-Site Locations \(5 through 11 years of age\)](#)

These materials and additional information is available [here](#) at the CDC Pfizer-BioNTech Product Information Clinical Resource webpage.

Question of the week:

Question: What dose and product do I use if a child is turning 12 years old between their first and second dose of the Pfizer vaccine series?

Answer: The dosage and product should be based on the child's age on the day of vaccination. Children aged 5 through 11 years should receive the 10 µg Pfizer-BioNTech COVID-19 Vaccine (**orange cap**) formulation, and adolescents aged 12 years and older should receive the 30 µg Pfizer-BioNTech COVID-19 Vaccine (**purple cap**) formulation. Therefore, if a child turns 12 years old between their first and second dose, they should receive the age-appropriate 30 µg Pfizer-BioNTech COVID-19 Vaccine (**purple cap**) formulation or COMIRNATY for their second dose to complete their series.

- If a child turns from 11 to 12 years of age in between their first and second dose and receives the 5–11 years (**orange cap**) for their second dose, they do not need to repeat the dose, and this is not considered an error under the EUA.
- **Children should receive the age-appropriate vaccine formulation regardless of their size or weight.**

If you have questions, please contact checcimms@michigan.gov

Thank you for all your hard work to protect Michiganders from vaccine-preventable diseases!

-The Immunization Nurse Education Team,
Andrea, Dianne, Heidi, Maria, Sarah, and Terri